Followers | 836 |
Posts | 120312 |
Boards Moderated | 18 |
Alias Born | 09/05/2002 |
![](https://investorshub.advfn.com/uicon/14742.png?cb=1465058685)
Thursday, March 25, 2021 10:41:30 AM
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent IMMP News
- Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- Immutep to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 08/07/2024 12:00:00 PM
- Immutep Quarterly Activities Report Q4 FY24 • GlobeNewswire Inc. • 07/31/2024 12:00:00 PM
- Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 07/22/2024 12:00:00 PM
- Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression • GlobeNewswire Inc. • 07/11/2024 10:40:40 PM
- Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results • GlobeNewswire Inc. • 07/03/2024 12:00:00 PM
- Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- Immutep successfully completes institutional placement and institutional component of entitlement offer • GlobeNewswire Inc. • 06/05/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 11:35:55 AM
- Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial • GlobeNewswire Inc. • 06/03/2024 12:38:39 AM
- Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 • GlobeNewswire Inc. • 05/15/2024 12:00:00 PM
- Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Immutep Quarterly Activities Report Q3 FY24 • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B • GlobeNewswire Inc. • 04/24/2024 12:00:00 PM
- Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- Immutep Announces First Clinical Data from 90mg Dosing of Efti • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 09:01:56 PM
- Immutep Quarterly Activities Report Q2 FY24 • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 12/21/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 11:06:56 AM
- Immutep Receives A$2.6 million R&D Tax Incentive from French Government • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
- Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial • GlobeNewswire Inc. • 11/22/2023 01:00:00 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM